```html

Xanthomas (Ocular)

What is Xanthomas (ocular)?

Ocular xanthomas are yellow‑orange, plaque‑like deposits that appear on the surface of the eye, most often on the conjunctiva, eyelids, or the cornea. They are collections of lipid‑laden macrophages (also called foam cells) that accumulate in the tissue when cholesterol and other fats are present in excess. While the lesions themselves are usually painless and benign, they often signal an underlying disorder of lipid metabolism, such as very‑high cholesterol or triglyceride levels, and can be the first visible clue of a serious systemic disease.

The term “xanthoma” comes from the Greek word xanthos meaning “yellow.” In the eye, the deposits may appear as flat patches, slightly raised nodules, or, in rare cases, as a more diffuse corneal haze. The condition is primarily a dermatologic or ophthalmologic finding, but because it reflects systemic lipid imbalance, it is considered an important red flag for cardiovascular and metabolic health.

Common Causes

Ocular xanthomas are most frequently secondary to disorders that raise blood lipids. The most common underlying conditions include:

• Familial hypercholesterolemia (FH) – an autosomal‑dominant mutation that markedly raises LDL‑cholesterol.
• Familial combined hyperlipidemia – elevated LDL‑cholesterol and triglycerides.
• Familial dysbetalipoproteinemia (type III hyperlipoproteinemia) – abnormal ApoE leads to cholesterol & triglyceride accumulation.
• Very‑low‑density lipoprotein (VLDL) excess / hypertriglyceridemia – often seen in type IIb or type V patterns.
• Lipoprotein (a) elevation – an independent risk factor for atherosclerosis and xanthoma formation.
• Secondary hyperlipidemia due to diabetes mellitus – especially poorly controlled type 2 diabetes.
• Hypothyroidism – reduces LDL receptor activity, raising serum cholesterol.
• Nephrotic syndrome – loss of proteins stimulates hepatic lipoprotein synthesis.
• Cholesterol‑rich diets combined with sedentary lifestyle – can precipitate xanthomas in genetically predisposed people.
• Certain medications – e.g., corticosteroids, antiretroviral protease inhibitors, and some diuretics may worsen lipid profiles.

Associated Symptoms

Most patients notice the ocular lesions before any systemic symptoms appear. When other signs do develop, they can include:

• Skin xanthomas (tuberous, eruptive, or plane) on elbows, knees, buttocks, or palms.
• Palmar creases with yellowish discoloration (palmar xanthoma striatum).
• Chest or tendinous xanthomas (especially on Achilles tendon).
• Fatigue, especially after meals high in fat.
• Chest pain or shortness of breath – possible early atherosclerotic heart disease.
• Peripheral artery disease symptoms: leg cramps, cold feet.
• Abdominal pain or pancreatitis in severe hypertriglyceridemia.
• Signs of hypothyroidism: weight gain, cold intolerance, constipation.

When to See a Doctor

Because ocular xanthomas can be a harbinger of serious cardiovascular disease, prompt evaluation is warranted.

• If you notice a new yellow‑orange spot on the conjunctiva, eyelid, or cornea.
• When the lesion grows, becomes raised, or interferes with vision.
• If you have a personal or family history of high cholesterol, early heart attacks, or stroke.
• When you have other skin xanthomas or tendinous nodules.
• Any accompanying symptoms of chest pain, sudden shortness of breath, or unexplained fatigue.

Diagnosis

Evaluation combines a focused eye exam with systemic laboratory testing.

Ophthalmic Assessment

• Slit‑lamp examination – magnifies the lesion, determines location (conjunctival, corneal, eyelid) and depth.
• Fundus photography – documents baseline appearance for future comparison.
• Optical coherence tomography (OCT) – useful if corneal involvement threatens vision.

Laboratory Work‑up

• Fasting lipid panel (total cholesterol, LDL‑C, HDL‑C, triglycerides).
• Genetic testing for familial hypercholesterolemia (LDLR, APOB, PCSK9).
• Thyroid function tests (TSH, free T4).
• Blood glucose and HbA1c – screen for diabetes.
• Liver function tests – assess for secondary dyslipidemia.
• Urinalysis & serum albumin – evaluate for nephrotic syndrome.

Additional Imaging (if indicated)

• Carotid duplex ultrasound – checks for atherosclerotic plaques.
• Coronary calcium scoring CT – quantifies coronary artery disease risk.

Treatment Options

Treatment is two‑pronged: address the ocular lesion itself (usually not necessary unless vision‑threatening) and, more importantly, correct the underlying lipid disorder.

Medical Management

• Statins (e.g., atorvastatin, rosuvastatin) – first‑line agents that lower LDL‑C by 30‑50% and can cause regression of xanthomas within months.
• Ezetimibe – reduces intestinal cholesterol absorption; useful in combination with statins.
• PCSK9 inhibitors (evolocumab, alirocumab) – powerful LDL‑C reducers for patients with familial hypercholesterolemia who do not reach targets with statins alone.
• Fibrates (gemfibrozil, fenofibrate) – lower triglycerides; indicated especially for hypertriglyceridemic xanthomas.
• Omega‑3 fatty acid supplements – EPA/DHA can modestly lower triglycerides.
• Bile‑acid sequestrants (cholestyramine) – adjunctive therapy when statins are insufficient.
• Thyroid hormone replacement – if hypothyroidism is identified.
• Management of secondary causes (tight glycemic control in diabetes, ACE inhibitors/ARBs for nephrotic syndrome, lifestyle changes).

Ophthalmic Interventions

• In most cases, no direct eye treatment is needed; lesions often shrink as systemic lipids improve.
• If lesions threaten vision (e.g., dense corneal xanthoma), laser photocoagulation or surgical excision may be considered by a corneal specialist.

Home & Lifestyle Measures

• Heart‑healthy diet – emphasize vegetables, fruits, whole grains, legumes, nuts, and fatty fish; limit saturated fat, trans‑fat, and cholesterol.
• Weight management – losing 5‑10 % of body weight reduces LDL‑C and triglycerides.
• Regular aerobic activity – at least 150 minutes of moderate‑intensity exercise per week.
• Quit smoking – nicotine increases LDL oxidation and accelerates atherosclerosis.
• Limit alcohol intake – especially important for hypertriglyceridemia.

Prevention Tips

Because ocular xanthomas are a manifestation of systemic lipid excess, primary prevention centers on maintaining normal blood lipids throughout life.

• Screen cholesterol levels at least once every 4‑6 years beginning at age 20; earlier if there is a family history of early heart disease.
• Adopt a Mediterranean‑style diet early in life.
• Stay physically active; incorporate both cardio and resistance training.
• Control body weight and waist circumference.
• Monitor blood pressure and blood glucose regularly.
• If you have a known genetic lipid disorder, start pharmacologic therapy as soon as recommended by your physician.
• Schedule regular eye examinations, especially if you have known dyslipidemia – ophthalmologists can spot subtle ocular xanthomas before they become visible to you.

Emergency Warning Signs

Key Take‑aways

Ocular xanthomas are more than a cosmetic curiosity; they are a visual clue that cholesterol or triglycerides are dangerously high. Early recognition, comprehensive lipid evaluation, and aggressive management can prevent serious cardiovascular complications and often lead to the disappearance of the eye lesions themselves. If you notice yellow‑orange plaques on your eyes, schedule an eye exam and a lipid panel promptly—acting fast can safeguard both your vision and your heart.

---

Sources: Mayo Clinic, Cleveland Clinic, National Institute of Health (NIH) – National Heart, Lung, and Blood Institute, American Heart Association, WHO, Journal of Lipid Research, Ophthalmology (American Academy of Ophthalmology) guidelines.

```